JP2002544231A - ガンを治療するための組成物とｅｔ７４３の使用 - Google Patents

ガンを治療するための組成物とｅｔ７４３の使用

Info

Publication number
JP2002544231A
JP2002544231A JP2000617900A JP2000617900A JP2002544231A JP 2002544231 A JP2002544231 A JP 2002544231A JP 2000617900 A JP2000617900 A JP 2000617900A JP 2000617900 A JP2000617900 A JP 2000617900A JP 2002544231 A JP2002544231 A JP 2002544231A
Authority
JP
Japan
Prior art keywords
cancer
administering
treating
dose
human patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000617900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002544231A5 (enExample
Inventor
エステバン・シヴィトコヴィッチ
ジョージ・ダニエル・デメトリ
セシリア・グスマン
ホセ・ヒメーノ
ルイス・ロペス・ラサロ
ジャン・ルイ・ミセ
シー・トゥエルヴズ
ダニエル・ディ・ヴォン・ホフ
Original Assignee
ファルマ・マール・ソシエダード・アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by ファルマ・マール・ソシエダード・アノニマ filed Critical ファルマ・マール・ソシエダード・アノニマ
Publication of JP2002544231A publication Critical patent/JP2002544231A/ja
Publication of JP2002544231A5 publication Critical patent/JP2002544231A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2000617900A 1999-05-13 2000-05-15 ガンを治療するための組成物とｅｔ７４３の使用 Withdrawn JP2002544231A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GB9911183.3 1999-05-13
GB9911346.6 1999-05-14
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GB9918534.0 1999-08-05
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GB9927005.0 1999-11-15
GB9927106.6 1999-11-16
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637.2 2000-03-29
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound
PCT/GB2000/001857 WO2000069441A1 (en) 1999-05-13 2000-05-15 Compositions and uses of et743 for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012105249A Division JP5777562B2 (ja) 1999-05-13 2012-05-02 ガンを治療するための組成物とｅｔ７４３の使用

Publications (2)

Publication Number Publication Date
JP2002544231A true JP2002544231A (ja) 2002-12-24
JP2002544231A5 JP2002544231A5 (enExample) 2007-06-21

Family

ID=27546594

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000617900A Withdrawn JP2002544231A (ja) 1999-05-13 2000-05-15 ガンを治療するための組成物とｅｔ７４３の使用
JP2012105249A Expired - Lifetime JP5777562B2 (ja) 1999-05-13 2012-05-02 ガンを治療するための組成物とｅｔ７４３の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012105249A Expired - Lifetime JP5777562B2 (ja) 1999-05-13 2012-05-02 ガンを治療するための組成物とｅｔ７４３の使用

Country Status (32)

Country Link
US (1) US8119638B2 (enExample)
EP (3) EP1702618B1 (enExample)
JP (2) JP2002544231A (enExample)
KR (1) KR20020019914A (enExample)
CN (2) CN100477993C (enExample)
AR (1) AR028476A1 (enExample)
AT (3) ATE375795T1 (enExample)
AU (2) AU777417B2 (enExample)
BG (1) BG65680B1 (enExample)
BR (1) BR0010531A (enExample)
CA (1) CA2373794C (enExample)
CY (4) CY1105818T1 (enExample)
CZ (1) CZ301482B6 (enExample)
DE (4) DE122008000013I1 (enExample)
DK (3) DK1716853T3 (enExample)
ES (2) ES2272279T3 (enExample)
FR (1) FR08C0013I2 (enExample)
HU (2) HU229866B1 (enExample)
IL (2) IL146434A0 (enExample)
LU (1) LU91418I2 (enExample)
MX (1) MXPA01011562A (enExample)
MY (1) MY164077A (enExample)
NL (1) NL300337I2 (enExample)
NO (2) NO324564B1 (enExample)
NZ (1) NZ515423A (enExample)
PL (1) PL198185B1 (enExample)
PT (3) PT1176964E (enExample)
SI (3) SI1702618T1 (enExample)
SK (1) SK287580B6 (enExample)
TR (1) TR200103819T2 (enExample)
UA (1) UA74782C2 (enExample)
WO (1) WO2000069441A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511498A (ja) * 2003-11-14 2007-05-10 ファーマ・マール・エス・アー・ウー Ｅｔ−７４３とドキソルビシンとを使用することを含むガンの併用療法
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
JP2019504061A (ja) * 2016-02-04 2019-02-14 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． トラベクテジンの注射可能な胃腸外用医薬組成物及びその製造方法
JP2023539578A (ja) * 2020-08-26 2023-09-15 アンチュレック ファーマシューティカルズ ゲーエムベーハー 軟組織肉腫を処置する際に使用されるためのｔＴＦ－ＮＧＲを含む組成物
JP2024521122A (ja) * 2021-05-19 2024-05-28 ファルマ、マール、ソシエダード、アノニマ エキュベクテディンのための投薬レジメン

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
JP2008505862A (ja) * 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
RS50822B (sr) * 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2007134203A2 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
CA3176956A1 (en) 2020-04-15 2021-10-21 Ever Valinject Gmbh Composition comprising trabectedin and an amino acid
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
WO1998054966A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. A method of treating cancer
JPH1129497A (ja) * 1997-05-15 1999-02-02 Hoechst Ag インビボ許容性の向上した製剤
WO1999020264A1 (en) * 1997-10-17 1999-04-29 Bionumerik Pharmaceuticals, Inc. Formulations and methods for reducing toxicity of antineoplastic agents

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
EP0309477B1 (en) * 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
WO1994026250A1 (en) * 1993-05-14 1994-11-24 Depotech Corporation Method for treating neurological disorders
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
BR9909488B1 (pt) 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
IL139607A0 (en) * 1998-05-11 2002-02-10 Pharma Mar Sa Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
KR100886496B1 (ko) 2000-04-12 2009-03-05 파르마 마르, 에스.에이. 항종양성 엑티나시딘 유도체
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
US20020137663A1 (en) 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
WO2002036135A2 (en) 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
PL368458A1 (en) 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2007511509A (ja) 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
JP2008505862A (ja) 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
WO2006035244A2 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RS50822B (sr) 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
JP2009517403A (ja) 2005-11-25 2009-04-30 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー Ｐａｒｐ−１阻害剤の使用
WO2007134203A2 (en) 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
JPH1129497A (ja) * 1997-05-15 1999-02-02 Hoechst Ag インビボ許容性の向上した製剤
WO1998054966A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. A method of treating cancer
WO1999020264A1 (en) * 1997-10-17 1999-04-29 Bionumerik Pharmaceuticals, Inc. Formulations and methods for reducing toxicity of antineoplastic agents

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511498A (ja) * 2003-11-14 2007-05-10 ファーマ・マール・エス・アー・ウー Ｅｔ−７４３とドキソルビシンとを使用することを含むガンの併用療法
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
JP2019504061A (ja) * 2016-02-04 2019-02-14 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． トラベクテジンの注射可能な胃腸外用医薬組成物及びその製造方法
JP2023539578A (ja) * 2020-08-26 2023-09-15 アンチュレック ファーマシューティカルズ ゲーエムベーハー 軟組織肉腫を処置する際に使用されるためのｔＴＦ－ＮＧＲを含む組成物
JP7823028B2 (ja) 2020-08-26 2026-03-03 アンチュレック ファーマシューティカルズ ゲーエムベーハー 軟組織肉腫を処置する際に使用されるためのｔＴＦ－ＮＧＲを含む組成物
JP2024521122A (ja) * 2021-05-19 2024-05-28 ファルマ、マール、ソシエダード、アノニマ エキュベクテディンのための投薬レジメン

Also Published As

Publication number Publication date
LU91418I9 (enExample) 2019-01-02
CY1105818T1 (el) 2011-02-02
NO20015516D0 (no) 2001-11-12
ES2294756T3 (es) 2008-04-01
EP1716853B9 (en) 2011-09-28
FR08C0013I2 (fr) 2009-10-30
IL146434A0 (en) 2002-07-25
FR08C0013I1 (enExample) 2008-05-30
AU777417B2 (en) 2004-10-14
TR200103819T2 (tr) 2002-04-22
DK1176964T3 (da) 2007-01-15
KR20020019914A (ko) 2002-03-13
PT1176964E (pt) 2007-01-31
NO324564B1 (no) 2007-11-19
ATE338552T1 (de) 2006-09-15
EP1716853B1 (en) 2011-03-09
LU91418I2 (fr) 2008-05-13
HUS1500001I1 (hu) 2016-08-29
HUP0201187A3 (en) 2002-11-28
AR028476A1 (es) 2003-05-14
CZ301482B6 (cs) 2010-03-17
BG65680B1 (bg) 2009-06-30
US20070275942A1 (en) 2007-11-29
ES2272279T3 (es) 2007-05-01
WO2000069441A1 (en) 2000-11-23
DE60036826D1 (de) 2007-11-29
CN1360503A (zh) 2002-07-24
CA2373794A1 (en) 2000-11-23
SI1176964T1 (sl) 2007-02-28
BR0010531A (pt) 2002-06-04
JP5777562B2 (ja) 2015-09-09
AU2005200180A1 (en) 2005-02-10
DE60030554D1 (de) 2006-10-19
AU4597500A (en) 2000-12-05
CN1679631A (zh) 2005-10-12
EP1176964A1 (en) 2002-02-06
SK16442001A3 (sk) 2002-03-05
BG106171A (en) 2002-06-28
PL352931A1 (en) 2003-09-22
EP1702618A3 (en) 2006-12-27
DE60030554T2 (de) 2007-09-13
AU2005200180B9 (en) 2008-05-29
PL198185B1 (pl) 2008-06-30
NL300337I1 (nl) 2008-05-01
PT1716853E (pt) 2011-05-12
EP1176964B8 (en) 2007-10-10
NZ515423A (en) 2004-04-30
ATE500830T1 (de) 2011-03-15
EP1702618A2 (en) 2006-09-20
NO2008005I1 (no) 2008-06-09
NO2008005I2 (enExample) 2010-09-27
HU229866B1 (en) 2014-10-28
EP1716853A3 (en) 2006-11-15
CY2008007I1 (el) 2009-11-04
SI1716853T1 (sl) 2011-10-28
CY2008007I2 (el) 2009-11-04
EP1716853A2 (en) 2006-11-02
JP2012149095A (ja) 2012-08-09
MXPA01011562A (es) 2002-07-30
EP1702618B1 (en) 2007-10-17
CA2373794C (en) 2005-10-11
PT1702618E (pt) 2008-01-11
MY164077A (en) 2017-11-30
CY1107143T1 (el) 2010-07-28
DK1702618T3 (da) 2008-02-25
SI1702618T1 (sl) 2008-02-29
DE122008000013I1 (de) 2008-08-07
EP1176964B1 (en) 2006-09-06
US8119638B2 (en) 2012-02-21
UA74782C2 (uk) 2006-02-15
DK1716853T3 (da) 2011-06-27
DE60036826T2 (de) 2008-08-28
CZ20014081A3 (cs) 2002-11-13
ATE375795T1 (de) 2007-11-15
CY1112753T1 (el) 2016-02-10
DE60030554T8 (de) 2008-01-10
IL146434A (en) 2008-03-20
DE60045720D1 (de) 2011-04-21
AU2005200180B2 (en) 2007-12-13
NO20015516L (no) 2002-01-11
SK287580B6 (sk) 2011-03-04
HUP0201187A2 (en) 2002-09-28
CN100477993C (zh) 2009-04-15
NL300337I2 (nl) 2008-09-01

Similar Documents

Publication Publication Date Title
JP5777562B2 (ja) ガンを治療するための組成物とｅｔ７４３の使用
AU2002343548B2 (en) Improved use of antitumoral compound in cancer therapy
US20090298752A1 (en) Aplidine treatment of cancers
AU2002343548A1 (en) Improved use of antitumoral compound in cancer therapy
JP2009536956A (ja) 抗癌治療法
RU2266734C2 (ru) Композиции и применение ет743 для лечения злокачественных опухолей
ES2363064T3 (es) Tratamiento de cánceres del cuerpo humano utilizando et743.
NZ529801A (en) Compositions and uses of ET743 for treating cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120502

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120524